PLOS Medicine Impact Factor

The spike to 15.8 in 2023 was driven by heavily cited COVID-related publications from 2021-2022. The return to 9.9 represents normalization, not decline. PLOS Medicine has been consistently in the 9-11 range for most of the past decade.

PLOS Medicine's editorial scope is narrower than its name suggests. It doesn't just want "medical research." It wants research with clinical or policy implications that affect patient care or public health at scale.

What gets published:

• Large randomized controlled trials with practice-changing potential
• Meta-analyses and systematic reviews that resolve clinical controversies
• Observational studies with strong causal inference and large sample sizes
• Global health research (infectious disease in low-income settings, maternal health, vaccine deployment)
• Health policy analyses with direct implications for decision-makers
• Modeling studies that inform public health response (epidemic modeling, cost-effectiveness analyses)

What gets desk-rejected:

• Single-center studies without generalizable implications. If your results only apply to one hospital or one country, editors won't see the scope.
• Basic science without a direct clinical angle. Even translational work gets redirected to PLOS Biology unless there's a clear path to patients.
• Pilot studies, case series, and small-sample exploratory work. PLOS Medicine wants definitive evidence, not preliminary signals.
• Clinical guidelines or expert opinion pieces without original data.

A specific rejection pattern worth knowing: PLOS Medicine rejects well-conducted studies that confirm what's already known. If your RCT demonstrates that a proven intervention works in a new population, that's useful but not PLOS Medicine material unless the population-specific findings change clinical recommendations.

PLOS Medicine uses an unusual hybrid of professional and academic editors. A full-time editorial team makes initial scope decisions, then working scientists serve as academic editors for peer review. This means your paper is first screened by someone who reads hundreds of submissions monthly (calibrated, efficient), then evaluated by someone who knows the specific field deeply.

The journal also publishes "Collection" articles, invited editorials, and "Medicine and Inequality" pieces that address structural barriers in healthcare. This editorial voice is part of what differentiates PLOS Medicine from more traditional general medicine journals.

PLOS Medicine accepts approximately 5-8% of submissions, making it one of the most selective open access journals. The editorial desk rejection rate is high, around 75-80%.

Typical timeline:

• Editorial assessment: 1-2 weeks (most rejections happen here)
• Peer review: 6-10 weeks (2-3 reviewers)
• First decision after review: 8-12 weeks total
• Revision period: 2-4 months
• Total submission to acceptance: 5-8 months

Like PLOS Biology, PLOS Medicine offers pre-submission inquiries. Send a structured abstract to the editors before writing the full manuscript. They'll tell you within a week whether the work fits the journal's scope. This is genuinely useful given the 75%+ desk rejection rate.

The $5,300 APC is steep, but it covers gold open access under CC BY. Your paper is freely available immediately upon publication, and anyone can reuse it with attribution.

Fee waivers work the same way across all PLOS journals. You request a waiver at submission, and it's evaluated on financial need regardless of country. The editorial decision is independent of ability to pay. PLOS has been transparent about this policy since the organization launched.

Institutional publishing agreements with PLOS can cover APCs. Check your library's arrangements. Many universities in Europe, North America, and Australia have PLOS agreements in place.

Submit if:

• Your study has clear implications for clinical practice or health policy at scale
• You have a large, well-powered RCT, meta-analysis, or observational study with strong causal methods
• You're in global health, infectious disease epidemiology, or health systems research
• You want full open access and support preprint posting
• The work addresses health equity or underserved populations (a PLOS Medicine editorial priority)

Think twice if:

• Your study is a single-site clinical observation without broad implications (try BMJ Open)
• You need an IF above 15 for career purposes (try The BMJ or JAMA)
• Your work is basic or translational without patient-level outcomes (try PLOS Biology)
• The $5,300 APC is a barrier and you don't qualify for a waiver

PLOS Medicine at 9.9 is a legitimate top-tier medical journal. It sits below The BMJ, The Lancet, and JAMA in raw impact factor, but it publishes research of comparable methodological quality in many areas. Its open access model, transparent peer review, and editorial commitment to global health and equity make it distinctive.

For clinical researchers, public health specialists, and global health researchers with strong, definitive findings that affect how medicine is practiced, PLOS Medicine is one of the best open access options available. The 5-8% acceptance rate means it's competitive, but the pre-submission inquiry system lets you test the waters before investing months in formatting and submission.

1. OpenAlex - PLOS Medicine: 5,711 works, h-index 349, 761,189 citations, APC $5,300
2. PLOS Medicine editorial policies - pre-submission inquiries, academic editor model
3. PLOS fee waiver policy - need-based review independent of editorial decisions

Preparing a clinical manuscript? Our AI manuscript diagnostic evaluates your paper's methodology, reporting compliance, and journal fit in about 30 minutes for $29.